Phospholipase C delta-1 (PLCD1)

Phospholipase C delta-1 (PLCD1) is an enzyme in the phospholipase C family critically involved in intracellular signal transduction. It hydrolyzes the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol triphosphate (IP3), which act as second messengers in diverse pathways including calcium signaling. PLCD1 is expressed in many tissues, with essential roles in skin homeostasis and placental development. Functionally, PLCD1 acts as a tumor suppressor: lower PLCD1 expression is associated with higher malignancy in several cancers, including chondrosarcoma and lung adenocarcinoma. Overexpression induces DNA damage and apoptosis, suggesting a potential therapeutic role, though no direct modulators exist clinically. PLCD1 mutations are implicated in hereditary leukonychia and congenital nail disorders. Key molecular markers linked with PLCD1 function include PCNA, caspase proteins, and DNA damage response molecules[1][2][5][6][4].

Other names

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1PLC-IIIPLC-delta-1Phosphoinositide phospholipase C-delta-1Phospholipase C-IIIPhospholipase C-delta-1Phospholipase C δ1NDNC3Phospholipase C I 1epididymis secretory sperm binding protein

Not currently defined for direct PLCD1-targeting therapies (no direct clinical drugs). Hypothetical: PLCD1 activation would hydrolyze PIP2, leading to cell cycle arrest, DNA damage, and apoptosis in cancer cells; caspase inhibition counteracts PLCD1-induced apoptosis[2][6]. PLCD1 downregulation facilitates cancer cell proliferation, migration, and epithelial–mesenchymal transition (EMT)[5].